Skip to main content

Table 4 FACT-BMT, FACT-Cog and PHQ-4 according to cGvHD

From: Impact of chronic graft-versus-host disease on quality of life and cognitive function of long-term transplant survivors after allogeneic hematopoietic stem cell transplantation with total body irradiation

Mean (SD)

All (n = 32)

Group 1: Never cGvHD (n = 10)

Group 2: Resolved cGvHD (n = 11)

Group 3: active cGvHD (n = 11)

F-value

p-value

Functional Assessment of Cancer Therapy-Cognitive function (FACT-Cog)

Perceived cognitive impairment (PCI, score range 0–72)

63.9(6.3)

67.0(5.2)a

66.1(4.6)a

58.8(5.8)b

7.8

.002*

Comments from others (Oth, score range 0–16)

15.6(.84)

15.7(.9)

15.7(.5)

15.4(1.0)

.621

.545

Impact of perceived cognitive impairments on quality of life (QoL, score range 0–16)

14.2(1.7)

15.0(1.1)a

15.0(1.0)a

12.9(1.9)b

7.8

.002*

Perceived cognitive abilities (PCA, score range 0–28)

22.5(4.1)

24.8(3.2)a

23.8(3.0)a

19.2(3.9)b

8.4

.001**

Functional Assessment of Cancer Therapy-Bone marrow transplantation (FACT-BMT)

Physical wellbeing (PWB, score range 0–28)

23.1 (4.8)

26.3 (2.1)a

25.8 (2.3)a

17.4 (3.2)b

39.9

 < .001***

Emotional wellbeing (EWB, score range 0–24)

19.3 (3.8)

21.7 (2.5)a

21.0 (2.2)a

15.5 (3.1)b

17.0

 < .001***

Social/family wellbeing (SWB, score range 0–28)

21.0 (3.8)

23.7 (1.0)a

22.5 (3.0)a

17.0 (2.6)b

23.6

 < .001***

Functional wellbeing (FWB, score range 0–28)

21.1 (3.6)

22.8 (1.8)a

23.8 (1.3)a

16.8 (2.1)b

46.7

 < .001***

Bone marrow transplant subscale (BMTS, score range 0–40)

30.8 (4.3)

33.4 (2.5)a

33.0 (2.7)a

26.4 (3.3)b

20.3

 < .001***

FACT-G total score (score range 0–108)

84.6 (14.0)

94.4 (5.3)a

92.8 (6.7)a

67.5 (7.0)b

59.1

 < .001***

FACT-BMT-Trial Outcome Index (TOI, score range 0–96)

75.1 (11.5)

82.4 (4.6)a

82.3 (5.0)a

61.4 (7.1)b

48.4

 < .001***

FACT-BMT total score (score range 0–148)

115.5 (17.8)

127.8 (6.7)a

125.8 (7.9)a

93.9 (9.9)b

56.5

 < .001***

Patient Health Questionnaire-4 (PHQ-4, score range 0–12)

1.94 (2.1)

1.3 (1.4)a

.91 (.94)a

3.6 (2.5)b

7.0

 < .001***

PHQ-2 (score range 0–6)

1.09 (1.3)

.8 (.9)a

.45 (.82)a

2.0 (1.4)b

6.1

 < .01**

GAD-2 (score range 0–6)

.84 (1.0)

.5 (.7)a

.45 (.52)a

1.5 (1.3) b

5.0

 < .05*

  1. cGvHD: chronic graft-versus-host disease; Never cGvHD: never having cGvHD; Resolved cGvHD: patients with a past history of cGvHD, no immunosuppression; Active cGvHD: physician reported currently active inflammatory manifestations of cGvHD; FACT-BMT and FACT-Cog: higher scores indicate better quality of life; Patient Health Questionaire (PHQ-4): measurement of core symptoms of depression (PHQ-2) and anxiety (GAD-2)
  2. Analysis of variance (ANOVA) with post-hoc Tukey-test: *p < .05, **p < .01, ***p < .001
  3. Groups with different letters (a, b) differ significantly at 5% significance level by the Tukey-test. Equal letters do not differ by the Tukey-test